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Abstract
Background: The blood brain barrier (BBB) is impermeable to most drugs, impeding the establishment of novel
neuroprotective therapies and strategies for many neurological diseases. Intranasal administration offers an alternative path
for efficient drug delivery into the CNS. So far, the anatomical structures discussed to be involved in the transport of
intranasally administered drugs into the CNS include the trigeminal nerve, olfactory nerve and the rostral migratory stream
(RMS), but the relative contributions are debated.
Methods and Findings: In the present study we demonstrate that surgical transection, and the resulting structural
disruption of the RMS, in mice effectively obstructs the uptake of intranasally administered radioligands into the CNS.
Furthermore, using a fluorescent cell tracer, we demonstrate that intranasal administration in mice allows agents to be
distributed throughout the entire brain, including olfactory bulb, hippocampus, cortex and cerebellum.
Conclusions: This study provides evidence of the vital role the RMS has in the CNS delivery of intranasally administered
agents. The identification of the RMS as the major access path for intranasally administered drugs into the CNS may
contribute to the development of treatments that are tailored for efficient transport within this structure. Research into the
RMS needs to continue to elucidate its limitations, capabilities, mechanisms of transport and potential hazards before we
are able to advance this technique into human research.
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Introduction
The treatment of acute or chronic neuropathological diseases
with drugs poses a unique challenge to medical science due to the
difficulties associated with crossing the blood brain barrier (BBB).
This is the principal impediment for systemically administered
drugs attempting to reach a target within the brain. Tight
junctions formed by occludins, claudins and other adhesion
molecules effectively block most molecules greater than 600
Daltons and limit paracellular penetration of the BBB [1]. A low
Ionic strength buffer with high electrostatic potential has also been
found to be important when attempting to increase BBB
penetration [2]. Other possible routes across the BBB include:
transcellular uptake through at least two lipid bilayers via
endocytosis, carrier-mediated transport through the use of specific
receptors, or peptide-mediated transport. Attempts have been
made to increase BBB penetration by increasing the systemic dose;
however, the concentrations necessary to penetrate this barrier
and exert an effect in the central nervous system (CNS) can have
deleterious systemic side effects [3]. Therefore, there is interest in
identifying more direct access routes into the CNS other than
systemic administration. Currently available direct modalities
include intraventricular and intraparenchymal administration;
cost, time, inconvenience, invasiveness and lack of efficacy make
these options of poor clinical utility. A more novel route is
intranasal administration, which allows agents to be rapidly
delivered to the CNS and avoids the negative aspects of systemic
administration. Agents are thought to traverse the nasal mucosa
into the CNS via the olfactory and trigeminal nerves [4–6];
however, details of intranasal uptake remain elusive.
Many drugs administered intranasally have been able to reach
the CNS and exert a therapeutic effect in humans. Melanocortin
delivered intranasally rapidly enters the CNS without systemic
spread, resulting in weight reduction after treatment for 6 weeks
[7,8]. Intranasal insulin has been studied for the treatment of
diabetes, and more successfully so, in Alzheimer disease with
patients showing improvements in attention, memory and
cognitive function [9,10]. Losartan administered intranasally in a
mouse model of Alzheimer disease resulted in a decrease in plaque
surface area and inflammatory mediators [11]. Intranasal versus
intravenous naloxone was compared in a human randomized
controlled trial that showed both administration routes produced
equivalent responses in patients [12]. Our lab and others have
shown that both erythropoietin (EPO) and Insulin-Like Growth
Factor I (IGF-I), when given intranasally, can enter the CNS in
high concentrations in rodent models [5,13–16]. In addition,
intranasally administered EPO and IGF-I rapidly accumulates in
the brain at significantly higher levels than after intravenous,
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in a reduction of stroke volume and improvement in behavioral
function in mice. Intranasal administration of PEGylated trans-
forming growth factor alpha was also studied in a rodent stroke
model that resulted in behavioral improvements and increased
proliferation of neuroprogenitor cells [18]. Kang et al. (2010) also
demonstrated neuroprotection with a murine model of human
immunodeficiency virus-associated neurocognitive disorders
(HAND), finding that intranasal EPO + IGF-I act synergistically
to activate signaling pathways which decrease the hyperpho-
sphorylation of tau protein [19]. Tau protein hyperphosphoryla-
tion has been found in brains of both humans with HAND, and
the murine model, to be associated with neuronal damage and
loss.
The transport pathway taken by intranasally administered drugs
into the various parts of the CNS is not completely understood.
The Rostral Migratory Stream (RMS), which connects the
olfactory bulb to the periventricular regions and is well described
in rodents [20,21], is potentially the missing structural link for the
transport of intranasally delivered drugs into the CNS. Altman et
al. (1965) observed dividing cells and neurons in the brain
following injury; this led to further investigation of these cells and
their destination in the non-pathologic state and the discovery of
the RMS [22–24]. Recently, the location, route, structure, and
potential function of the RMS have been further characterized in
multiple animal models. The inferiolateral wall of the lateral
ventricles in the mammalian brain forms the subventricular zone
(SVZ). Luskin et al. (1993) observed neuroprogenitor cells arising
in the SVZ appearing as interneurons in the glomerular and
periglomerular layers of the olfactory bulb (OB) and hypothesized
that there exists a route connecting the two areas [25]. This was
designated as the RMS, a path several millimeters in length
extending from the SVZ to OB. It is composed of stationary glial
cells and neuronal precursors that move in chains and splay out in
a radial pattern upon reaching the OB [20,21]. It has been
reported that the migration of neuroblasts coincides with a scaffold
of blood vessels and astrocytes, which are in particularly high
density in the RMS [26]. Dividing cells do lie in close proximity to
blood vessels (BV) in the early embryonic stages, but the
association is looser in postnatal stages, a possible indication that
the BV scaffolding doesn’t play a major role in migration;
however, trophic factors could be trapped by the blood vessels
providing a migratory signal [27]. Interestingly, compounds
introduced into the nasal cavity of rats and mice appear in large
concentrations in the OB and olfactory nerve, whereas other
routes of administration do not have the same ability to penetrate
the BBB [14,28,29]. Cells were also successfully introduced into
the nasal cavity of rats and mice and found to transport into both
the olfactory bulb, with ‘‘close association’’ to the RMS, as well as
to other parts of the cerebrum via circulation through the
cerebrospinal fluid [30]. In a rat Parkinson model, intranasally
delivered mesenchymal stem cells were found to be widely
distributed at four hours with multiple beneficial effects including
reduction of inflammatory cytokines and higher levels of both
thymidine hydroxylase and dopamine [31].
Many of the methods used to define the RMS in rodents cannot
be applied to human research. Literature points to the presence of
a human RMS, but the function at various stages of development
remains to be clarified [32]. Analysis of human fetal brains has
shown a ventral extension of the anterior horn of the lateral
ventricles that is analogous to the rodent RMS [33]. Additionally,
the distribution of doublecortin positive cells in human fetal brains
indicates similarities in rodent and human neuroblast migration
[33].
Most attention has focused on the caudal to rostral (antero-
grade) migration of neuroblasts within the RMS. Data shows that
intranasal administration of small peptides such IGF-I and EPO
produce high CNS concentrations in as short as twenty minutes
[14], suggesting the existence of a retrograde (rostral to caudal)
pathway. Little is known about a retrograde pathway or
mechanism to explain this transport of peptides and cells in
comparison to the better defined anterograde pathway.
In the present study, we used a fluorescent tracer, CellTracker
Green BODIPY, to determine whether intranasal administration
provides a sufficient pathway for delivering drugs to the brain. We
found that administering a fluorescent tracer into the nasal cavity
of mice produces high levels of fluorescence throughout multiple
regions of the brain, including the hippocampus, cortex and
cerebellum. Furthermore, in order to determine the role of the
RMS in the uptake of peptides into the brain, we used
radiolabeled
125I-EPO and
125I-Calcitonin. In a normal mouse,
we found significant quantities of both
125I-cytokines in the brain
20 min after intranasal administration; however, surgical transec-
tion of the RMS abolished uptake into the brain. Therefore, we
hypothesize that the intranasal pathway could provide a simple,
rapid, and non-invasive means of delivering peptides into the brain
via the RMS. The intranasal/RMS pathway could be applied to
the treatment of many conditions including stroke, traumatic brain
injury and neurodegenerative diseases.
Materials and Methods
Ethics Statement
All animals were housed in a supervised facility within the UT
Health Science Center in compliance with the Care and Use of
Laboratory Animals (Department of Health and Human Services),
the provisions of the Animal Welfare Act (U.S.D.A.) and all
applicable federal and state laws and regulations. The University
of Texas at San Antonio Animal Care and Use Committee
approved all animal care and use for this study (Approval ID:
07071).
Animals
Male C57Bl/6 mice, average weight of 22 g, were housed in
groups of 4 in a room with a 12 hour light/dark cycle with ad
libitum access to food and water. Animals used for the fluorescence
portion of this study were separated into two cohorts of three mice,
each cohort either received treatment with a fluorescent tracer or
the vehicle, phosphate buffered saline (PBS), as a control to rule
out autofluorescence. Animals in the radiolabeled portion of the
study were divided into cohorts of 18 who either received
125I-
EPO or
125I-Calcitonin. In each of these cohorts animals were
further divided into those who had surgical transaction of the
RMS (n=9) and the sham (control) group (n=9). Three mice in
each surgical group were euthanized at 20, 60, and 120 minutes.
Preparation of Fluorescent Tracers and Iodinated
Peptides
CellTracker Green BODIPY (CTG, Invitrogen, Catalog
#C2102) is a low molecular weight compound of 296 Daltons
that crosses cell membranes and is endogenously fluorescent. CTG
contains a thiol reactive portion, which undergoes a glutathione S-
transferase-mediated reaction within the cytoplasm of the cell,
making it impermeable to cell membranes, thereby trapping the
fluorescent tracer within the cell. Therefore, CTG provides a
novel tool to determine the possible distribution pattern of an
intranasally applied agent in the brain. CTG was solubilized in
anhydrous dimethylsulfoxide (DMSO, Sigma-Aldrich, Catalog
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working concentration of 50 or 25 mM using phosphate buffered
saline (PBS).
125I-EPO (3-[
125I] iodotyrosyl-Erythropoietin, human
recombinant [high specific activity], GE Healthcare, 2500 Ci/
mmol) and Calcitonin (3-[
125I]iodotyrosyl
2 human calcitonin,
Perkin Elmer, NEX423010UC, 2200 Ci/mmol) were dissolved
separately in vehicle (10 mM sodium succinate buffer containing
140 mM NaCl, pH 6.2).
Intranasal Delivery
Mice were placed supine on a thermo regulated surgical table
that maintained body temperature at 37uC. The table was
elevated to 30 degrees reverse Trendelenburg and anesthesia
was induced by isoflurane (1.5–2%, 30% O2) delivered via
facemask. Then, 6 ml of CTG,
125I-EPO,
125I-Calcitonin or
vehicle was delivered to the olfactory tissue in the nasal cavity by
alternate and slow administration into both nares over a period of
ten minutes using a microsyringe. Mice remained anesthetized for
an additional 20 minutes in the same position. The timing and
position allow the tracer of interest to be taken up via the olfactory
epithelium [34,35].
Transection of the Rostral Migratory Stream (RMS)
Anesthesia was induced by isoflurane (1.5–2%, 30% 02) and
delivered via facemask to mice positioned in a stereotaxic frame
and temperature maintained at 37uC with a heating blanket
(Harvard Apparatus, MA). We used the surgical procedure
described for bulbectomies to gain access to the olfactory bulb in
anesthetized mice [36,37]. After removing the skin over the OB
area, a burr-hole was drilled into the skull covering the OB/frontal
cortex, expanded to an elliptical shaped window (approx.
362 mm) and the location of the target tissue confirmed under
a microscope at a total magnification of 100x. The tip of a scalpel
blade number 11 was inserted into the window at an angle of 90u
to the fronto-occipital axis of the brain, and the tissue at the distal
portion of the olfactory bulb and the adjacent frontal cortex was
transected (figure 1A, B). After visual confirmation of successful
and complete separation of the OB, the burr-hole was closed with
bone cement. To allow the complete cessation of potential
bleeding and separation of the dissected tissue, intranasal
125I-
EPO or
125I-Calcitonin was administered 20 min after the
transection. We administered 5610
5 cpm of
125I-EPO or
5610
5 cpm of
125I-Calcitonin to each animal intranasally as
described above. Sham (control) animals underwent the same
surgical procedures described above, but without the transection of
the RMS/OB. All animals were kept anesthetized until their
designated tissue collection time (20, 60, or 120 minutes).
Tissue Processing and Visualization
For fluorescent imaging, mice were deeply anesthetized 5 hours
after intranasal administration and transcardially perfused using
normal saline followed by 4% paraformaldehyde (PFA). Samples
for peripheral blood smear were taken prior to perfusion. Tissue
samples were harvested, transferred to a solution of 4% PFA
overnight, cryoprotected in 30% sucrose in PBS for 48 hours,
frozen using liquid nitrogen cooled isopentane and sectioned to
12 mm using a cryostat (Leica). Sections were incubated in 100%
Acetone for ten minutes followed by three, five minute washes with
PBS. Sections were then mounted on coverslips with Prolong Gold
anti-fade reagent with or without DAPI (Invitrogen) and visualized
using an Olympus FV-1000 confocal microscope (Olympus
America Inc).
Bromodeoxyuridine
To illustrate the location of the RMS and transection in the
mouse brain, bromodeoxyuridine (BrdU, Invitrogen, 1 ml/100 g
body weight, Invitrogen, Catalog #000103) was administered
intraperitoneally to a mouse immediately following RMS transec-
tion, as well as a control mouse. After 24 hours brains were
harvested, fixed, and cryoprotected as described above, and 35 mm
sections were processed using standard immunofluorescence
techniques with BrdU monoclonal antibody Alexa Fluor 488
Figure 1. Mouse brain composite image illustrating olfactory bulb transection. Images were obtained on a Nikon confocal microscope
using a 206objective and reconstructed into a composite image using ImageJ MosaicJ. DAPI labels cell nuclei and is labeled blue, anti-BrdU labels
proliferating cells and is labeled green. Figure 1A is a representative image of a control (non-transected) brain, Figure 1B is a representative imageo fa
transected brain. Approximate location of the rostral migratory stream (RMS) is outlined between the solid red lines, lateral ventricles are labeled LV,
olfactory bulb is labeled OB, and the ends of the plane of transection are labeled with yellow arrows.
doi:10.1371/journal.pone.0018711.g001
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with Vectashield with DAPI. Images were obtained as a z-stack on
a Nikon confocal microscope using a 206 objective and
reconstructed into a composite image using ImageJ MosaicJ.
Liquid Scintillation Analysis
Liquid Scintillation Analysis (LSC) measures the incorporation
of
125I-EPO or
125I-Calcitonin into the brain and other tissues.
Kinetic energy contained in the radioactive labeled cytokines in
the tissue homogenates will be emitted as auger electrons and
converted by the scintillation liquid into light energy and
detected and quantified by a light sensitive detector. The total
number of photons from the excited fluor molecules constitutes
the scintillation. LSC was used to quantify the levels of
125I-EPO
or
125I-Calcitonin after intranasal administration in control and
RMS-transected mice. After administration, deeply anesthetized
mice were euthanized after time periods as indicated and
transcardially perfused with 10 ml of normal saline solution. This
procedure is performed to remove blood from the tissues to be
analyzed and to collect the blood to quantify systemic leakage of
125I-EPO or
125I-Calcitonin. After euthanasia, we collected the
cerebrum without the olfactory bulb to measure
125I-EPO or
125I-Calcitonin uptake into the brain. Lung tissue was also
collected to test whether the radioligands were aspirated, and a
swab of the nasal cavity was performed with liquid absorbing
filter paper to collect residual amounts of the radioligands in the
nasal cavity. All homogenized tissue samples and nasal swabs
were individually mixed with a liquid scintillation cocktail (1 ml
in 50 mM Tris-HCl, pH 7.4, Microscint, Packard) to a final
volume of 12 ml in a scintillation glass vial and measured, in
presence of calibrators (Perkin Elmer, I-125 Pico-Calibrator,
Catalog #5080125), in a scintillation counter (Topcount,
Packard). Measurement controls with quenched samples (with
nitromethane) and scintillation cocktail without radioactivity
were run in parallel as controls. LSC measurements are
expressed as the percent of radioactivity detected in the samples
compared to the amount applied. All statistical analysis was
performed using one-way ANOVA and a p-value,0.01 was taken
as statistically significant.
Results
Intranasal Administration of CellTracker Green
Intranasally delivered CTG (6 ml) was detected by microscopic
detection of CellTracker Green throughout the hippocampus and
cerebellum 5 hours after administration (Figure 2). CTG positive
cells were also detected in the olfactory bulb, cortex, and the
choroid plexus (Figure 3). Figure 4 demonstrates the areas of the
mouse brain that were imaged for Figures 2 and 3. CTG positive
cells were not observed in any peripherial tissue sample such as
kidney, lung, and liver from any subject in the CTG or control
group (images not shown). Peripherial blood smears to assess for
hematogenous dissemination of CTG were negative for any CTG
positive cells (images not shown).
Intranasal Administration of
125I-EPO &
125I-Calcitonin
after RMS Transection
The RMS in mice is located within the olfactory tract (OT)
[38]. To understand its role in the transport of peptides into the
brain after intranasal administration, we surgically transected the
RMS, thereby disrupting the normal flow.
125I-EPO or
125I-
Calcitonin was administered intranasally to RMS transected and
sham (control) mice. Mice were euthanized 20, 60 and 120
minutes following administration. Additional samples from the
blood, lungs, and nasal swabs were used to quantify systemic
leakage from both surgical and control groups. Samples were then
analyzed using liquid scintillation analysis (Figure 5). In the control
group (intact RMS), 20 minutes after administration, 41.3%6
5.1% of the applied intranasal
125I-EPO and 18.6%61.4% of the
applied intranasal
125I-Calcitonin was detected in the brain,
without significant amounts in the peripheral homogenates
including lung, blood and nasal swabs (Figure 5A, 5C). It is of
interest to note that 75.8%67.5% of the applied
125I-EPO is in the
brain after only 60 minutes. However, in the mice with a
transected RMS, only 3.3%60.9% of the applied intranasal
125I-
EPO and 4.2%60.7% of the applied intranasal
125I-Calcitonin
was detected in the brain samples with significant quantities found
in peripheral sites (Figure 5B, 5D).
Systemic leakage of intranasally administered
125I-EPO was
statistically negligible and did not significantly increase during the
observation period. Nasal swabs indicated that an insignificant
amount of
125I-EPO remains in the nasal cavity. In a similar
Figure 2. Intranasal uptake of CTG into the hippocampus and
cerebellum. Anesthetized mice received intranasal administration of
CTG (6 ml) or vehicle (PBS) into both nares slowly over a period of ten
minutes. Mice remained anesthetized for an additional 20 minutes in a
supine position to allow absorption of the tracer through the olfactory
epithelium and into the olfactory blub. Five hours later, mice were
euthanized and perfused with 4% PFA, and the brains sectioned into
12 mm slices. CTG positive cells are labeled green. Vehicle treated mice
did not produce any signal (data not shown).
doi:10.1371/journal.pone.0018711.g002
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125I-
Calcitonin was not statistically significant when compared to
CNS, but higher than the values for
125I-EPO. However,
systemic leakage for both radioligands increased significantly in
mice subjected to RMS transection, and high residual amounts
of
125I-EPO and
125I-Calcitonin were detectable in the nasal
cavity.
Discussion
In the present study the intranasal administration of low
molecular weight fluorescent probes and radioligands results in
accumulation of fluorescence and radioactive signal throughout
the brain, but not in peripheral tissues such as lungs and blood.
However, when the RMS is surgically transected, the radiolabeled
Figure 3. Intranasal uptake of CTG into the olfactory bulb, choroid plexus, and cortex. Anesthetized mice received intranasal
administration of CTG (6 ml) or vehicle (PBS). Mice remained anesthetized for an additional 20 minutes in a supine position. Five hours later, mice were
euthanized and perfused with 4% PFA, and the brains sectioned into 12 mm slices. Nuclei were counterstained with DAPI (Blue). CTG cells are labeled
green. No signal was detected in the vehicle treated mice (data not shown).
doi:10.1371/journal.pone.0018711.g003
Figure 4. Illustration showing the location of the RMS, where it was transected, and its relation to where images were obtained for
Figures 2 and 3.
doi:10.1371/journal.pone.0018711.g004
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statistically significant quantities in the brain. The volume chosen
for administration into the nasal cavity (6 ml) has been shown
previously to be the maximum volume that can be applied to the
olfactory tissue without subsequent systemic leakage. Therefore,
the presence of the radioligands in the peripheral tissue is unlikely
due to the volume administered into the nasal cavity. We
hypothesize that structural disruption of the RMS prevented
uptake into the CNS. This resulted in prolonged contact with the
respiratory tissue allowing the radioligands to take another path,
resulting in an increase in radioactive signal in the lung and blood
samples. We observed an increase in mucosal volume in the nasal
cavity after RMS transection. This increase in fluid volume may
also contribute to the likelihood that the radioligands are taken up
systemically via the circulatory system or aspirated into the lungs.
This is supported by the fact that the radioactivity is initially high
in the nasal swab samples, but diminishes over time. Moreover,
these results are indicative of the rapid uptake by the RMS which,
when intact, does not allow for the buildup of radioligands within
the nasal cavity. This is further supported by our findings that
125I-
EPO and
125I-Calcitonin are found in the CNS in significant
quantities within twenty minutes when compared to locations
outside the CNS. Therefore, our findings suggest that a
structurally intact RMS is necessary for the rapid uptake of
peptides into the CNS.
The trigeminal and olfactory nerves have been discussed as
potential access routes from the nasal cavity into the CNS
[6,13,39,40]. In rodents the RMS is embedded into the olfactory
nerve making RMS transection without injuring the olfactory
nerve surgically impossible. Therefore, we cannot exclude the role
of the olfactory nerve. However, were the olfactory nerve the main
route into the CNS, a more focused accumulation of the tracer
and radioligands in the projection areas of this nerve would be
expected. Our previously published results from autoradiographs
indicate that intranasally administered radioligands distribute
throughout the brain and are not confined to or concentrated in
the olfactory areas innervated by the olfactory nerve [39].
Moreover, tracers used in the present study did not show a
preference for the projection areas of the olfactory nerve. These
results indicate that either: a) the RMS, not the surrounding
Figure 5. Disruption of the RMS prevents intranasal delivery of peptides. Mice were anesthetized and the RMS dissected through a small
burr-hole over the olfactory bulb.
125I-EPO or
125I-Calcitonin was administered intranasally 20 minutes later. The mice were then euthanized after 20,
60, or 120 minutes, and radioactivity was measured in brain tissue, lung tissue, blood and nasal swabs using a scintillation counter (Perkin Elmer).
Data is expressed as a percentage of the total amount of the applied radioligand (mean 6 SD, n=3). *p,0.01, percent of radioligand in the brain
compared to lung, blood and nasal swabs at each time point.
#p,0.01, percent of radioligand in the brain compared to lung and blood only,
{p,0.01, percent of radioligand in the brain at 60 or 120 minutes versus in the brain at 20 minutes.
doi:10.1371/journal.pone.0018711.g005
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transported by the olfactory nerve bypass the olfactory region of the
brain. In this model the trigeminal nerve remains intact and may
provide a potential uptake path into the CNS. However, the
dramatic reduction of cerebral uptake of intranasally administered
peptides following the transection of the RMS indicates that the
trigeminal nerve may play a lesser role in CNS transport within the
time frame of this study. Nevertheless, it is entirely possible that all
structures named above might collectively provide an access path
intothebrain,butwith differentratesoftransportationanddifferent
target areas. Therefore, subsequent experiments that involve longer
administration periods than used in this study are needed.
The mechanisms of transport within the RMS are not
thoroughly addressed by this study; however, the rapidity of
uptake of both the fluorescent tracer and radioligands suggest a
paracellular mechanism rather than cell mediated. In addition, a
greater concentration of the fluorescent tracer would be expected
in the more rostral cells along the RMS were the mechanism
involved cell mediated or transcellular. This suggests that it is the
existence, and to some degree, the structure of the RMS that is
necessary, rather than the functionality; i.e. the movement of cells.
This makes surgical transection of the structure a desirable method
to evaluate its role. Severe reactive astrogliosis with scar formation
is likely to occur in the long term as a result of the direct trauma
caused by transection [41]. Astrocyte hypertrophy would only be
at the beginning stages at twenty minutes, gene up-regulation such
as GFAP mRNA takes an hour to be detected, and glial scar
formation would take greater than six hours [42,43]; however,
reactive astrogliosis and scar formation is unlikely to have a
significant effect in the short time frame of this study. The earliest
time-point at which hypertrophy is detectible in rats is 24 hours
after insult, reaching maximal response in 3–4 days; the human
response is further delayed with detection and maximum around 4
days and 2–3 weeks, respectively [44]. Interestingly, studies using a
longer time frame than this study in evaluating the movement of
cells after RMS transection, demonstrated PSA-NCAM positive
cells penetrating the glial scar [45].
We also cannot discount the possibility that results may be
different in genetic models with a dysfunctional RMS, often
resulting in olfactory bulb hypoplasia [46–48]. However, in these
models some degree of cellular migration along the RMS is still
present; more important, the architecture of the RMS remains
intact. Kaneko et al. (2010) recently provided evidence suggesting
that the Slit1 protein is used by new neurons to form and maintain
astrocyte tunnels, as well as alter astrocyte morphology [49]. This
model creates RMS dysfunction through structural alteration and
the results of repeating this investigation using Slit1 deficient mice
would be interesting; however, it is unclear whether the degree of
RMS structural disruption in Slit1 deficient mice is comparable to
RMS transection.
Numerous publications confirm the efficacy of intranasal
administration for the delivery of compounds and cells to the
CNS with the added benefit of minimal systemic spread
[6,11,18,31,50]. Various strategies have been employed in an
effort to increase uptake such as nanoparticles and PEGylation;
however, the intranasal pathway is so efficient these had minimal
effect or were negated by optimizing the ionic strength of the
buffer used [18]. Not all studies have had a successful treatment
effect despite high CNS concentrations of the compound
administered [51]. This illustrates an important caveat, the
intranasal pathway is not a cure-all for CNS disease, but it is a
highly efficient means of delivering agents that may or may not
have their own unique target and mechanism. Prior studies
hypothesized the pathway taken to the CNS following intranasal
administration to be a combination of the olfactory and trigeminal
nerve. However, a literature search failed to produce any studies
that used a physical transection of the proposed paths to
demonstrate loss of transport into the CNS. This study shows
that using intranasal administration, transection of the RMS
decreases CNS concentrations of radio-labeled peptides by over
80%. This suggests that the RMS is the major pathway used
following intranasal administration.
The intranasal pathway could provide an inexpensive, non-
invasive, and effective means of gaining high concentrations of
agents in the CNS without systemic side effects. This pathway
could be applied to the treatment of many conditions including
traumatic brain injury, stroke, and neurodegenerative disease.
This study has provided evidence of the vital role the RMS has in
the CNS delivery of intranasally administered agents. The
identification of the RMS as the major access path for intranasally
administered drugs may contribute to the development of
therapeutics tailored for efficient transport within this structure.
The transport capacity of the RMS is likely to be influenced by the
physiochemical properties of administered substances such as
molecular weight, solubility, charge and dissociation characteris-
tics. Research into the RMS needs to continue to elucidate its
limitations, capabilities, mechanisms of transport and potential
hazards before we are able to advance this technique into human
research.
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